SGLT2 Inhibitors for Adult Primary Nephrotic Syndrome
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a kidney biopsy confirming primary nephrotic syndrome (like membranous nephropathy, minimal change disease, or focal segmental glomerulosclerosis).
- Your kidney function is good enough: eGFR (a measure of how well your kidneys filter blood) must be 25 or higher.
- You have been on stable doses of your current kidney medicines and immune-suppressing drugs for at least 4 weeks before starting.
- You are willing and able to give informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This trial tests dapagliflozin, a daily medicine, to slow kidney problems in people with early-stage chronic kidney disease caused by Alport syndrome. It may help protect kidney function and reduce worsening over time.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.